RT Journal Article
SR Electronic
A1 Parry, Nicola
T1 Open-Label Extension of RIDE and RISE Shows Improved Visual Outcomes Maintained without Ranibizumab Retreatment
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 43
SP 7
OP 8
DO 10.1177/155989771443002
UL http://mdc.sagepub.com/content/14/43/7.abstract
AB This article presents data from the open-label extension study of the RIDE [A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema With Center Involvement Secondary to Diabetes Mellitus; NCT00473382] and RISE [A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema With Center Involvement Secondary to Diabetes Mellitus; NCT00473330] trials.